Compare · NPCE vs WST
NPCE vs WST
Side-by-side comparison of Neuropace Inc. (NPCE) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NPCE and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $26.96B, about 61.4x NPCE ($438.7M).
- Over the past year, NPCE is up 14.0% and WST is up 39.7% - WST leads by 25.7 points.
- WST has hit the wire 3 times in the past 4 weeks while NPCE has been quiet.
- WST has more recent analyst coverage (20 ratings vs 17 for NPCE).
- Company
- Neuropace Inc.
- West Pharmaceutical Services Inc.
- Price
- $12.25-3.92%
- $383.81+0.18%
- Market cap
- $438.7M
- $26.96B
- 1M return
- -13.73%
- +4.70%
- 1Y return
- +13.95%
- +39.66%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 3
- Recent ratings
- 17
- 20
Neuropace Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest NPCE
- CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 335 shares, decreasing direct ownership by 0.65% to 51,357 units (SEC Form 4) (for withholding tax)
- Chief Financial Officer Williams Patrick F. covered exercise/tax liability with 1,162 shares, decreasing direct ownership by 2% to 67,508 units (SEC Form 4) (tax liability)
- KeyBanc Capital Markets initiated coverage on NeuroPace with a new price target
- CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,310 shares, decreasing direct ownership by 0.94% to 138,000 units (SEC Form 4) (for tax liability)
- NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
- NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
- CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,126 shares, decreasing direct ownership by 0.80% to 139,310 units (SEC Form 4) to satisfy withholding obligation
- CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 358 shares, decreasing direct ownership by 0.69% to 51,692 units (SEC Form 4) (for withholding tax)
- Amendment: SEC Form SCHEDULE 13G/A filed by Neuropace Inc.
- SEC Form 10-Q filed by Neuropace Inc.
Latest WST
- West to Host Third-Quarter 2026 Conference Call
- West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Pharm upgraded by Morgan Stanley with a new price target
- Sr. VP & Chief HR Officer Favorite Annette F exercised 7,524 shares at a strike of $89.64 and sold $2,671,260 worth of shares (7,524 units at $355.03) (SEC Form 4)
- Sr. VP & Chief HR Officer Favorite Annette F exercised 8,135 shares at a strike of $85.37 and sold $2,772,489 worth of shares (8,135 units at $340.81) (SEC Form 4)
- SEC Form 4 filed by President and CEO Lagarde Michel
- New insider Lagarde Michel claimed ownership of 7,850 shares (SEC Form 3)
- UBS resumed coverage on West Pharm with a new price target
- West to Participate in Upcoming Investor Conferences